PCM
AVTX icon

Prelude Capital Management’s Avalo Therapeutics AVTX Stock Holding History

Prelude Capital Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-35,096
Closed -$524K – 1250
2026
Q1 		$524K Buy
+35,096
New +$549K 0.04% 485
2025
Q4 		– Sell
-24,628
Closed -$313K – 1298
2025
Q3 		$313K Buy
+24,628
New +$212K 0.02% 713
2020
Q3 		– Hold
0
– – – 1812
2020
Q2 		– Hold
0
– – – 1943

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Prelude Capital Management's AVTX Position: Q2 2026 in Review

Prelude Capital Management sold out of Avalo Therapeutics (AVTX) in Q2 2026, closing a stake of 35,096 shares — an estimated $524K sold.

Prelude Capital Management first reported a position in AVTX in Q3 2025 and held it in 2 quarters. The position peaked at $524K in Q1 2026. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • Prelude Capital Management reported no remaining Avalo Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Prelude Capital Management sold 35,096 Avalo Therapeutics shares in Q2 2026, an estimated $524K.
  • Prelude Capital Management first reported a position in Avalo Therapeutics in Q3 2025 and held it in 2 quarters.
  • Prelude Capital Management's Avalo Therapeutics position peaked at $524K in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.